Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Schizophrenia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Schizophrenia
    TopAbstracts in Schizophrenia 10/29/2009 - (DGNews)
    Use of Antipsychotic Medications by Children and Adolescents Associated With Significant Weight Gain - (DGNews)
    TopAbstracts in Schizophrenia 10/15/2009 - (DGNews)
    TopAbstracts in Schizophrenia 10/01/2009 - (DGNews)
    Patients Receiving Antipsychotic Treatment at High Risk of Cardiovascular Disease: Presented at ECNP - (DGDispatch)

    News archive

     Recent webcasts/CME - Schizophrenia

    Webcasts/CME archive

     Recent cases - Schizophrenia
      Graves' Disease Presenting as Paranoid Schizophrenia in a Nigerian Woman: A Case Report
      Schizophrenia-Like Psychosis Following Left Putamen Infarct: A Case Report
      Localisation Using Mini C-Arm Fluoroscopy of Needles Ingested by a Woman with Schizophrenia: A Case Report
      Schizophrenia Spectrum Disorders in a Nigerian Family: 4 Case Reports
      Massive Pulmonary Emboli Associated with Olanzapine

      Cases archive
        




      my personal edition > schizophrenia > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      Aripiprazole Receives Expanded Paediatric Indications for Bipolar I Disorder and Schizophrenia

      TOKYO and PRINCETON, NJ -- May 9, 2008 -- Aripiprazole (Abilify) is now indicated for maintenance treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in paediatric patients aged 10 to 17 years and for maintenance treatment of schizophrenia in adolescents aged 13 to 17 years. In addition, aripiprazole also is approved as adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in paediatric patients aged 10 to 17 years.

      Aripiprazole was recently approved for the acute treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in paediatric patients aged 10 to 17 years in February 2008 and for the acute treatment of schizophrenia in adolescents aged 13 to 17 years in October 2007. The US Food and Drug Administration first approved aripiprazole for the treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in adults in September 2004 and for the treatment of schizophrenia in adults in November 2002.

      The safety and effectiveness of aripiprazole in paediatric patients with bipolar mania were established in a 4-week, placebo-controlled clinical trial in 197 paediatric patients (aged 10-17 years). The safety and effectiveness of aripiprazole in adolescents with schizophrenia were established in a 6-week, placebo-controlled clinical trial in 202 paediatric patients (aged 13-17 years). Although maintenance efficacy in these patient populations has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adults and paediatric patients.

      There is no body of evidence available to answer the question of how long the adolescent patient treated with aripiprazole should be maintained. It is generally recommended that responding patients be continued beyond the acute response but at the lowest dose needed to maintain remission. Periodic reassessment should be conducted to determine the need for maintenance treatment.

      The efficacy of adjunctive aripiprazole with concomitant lithium or valproate in the treatment of manic or mixed episodes in paediatric patients has not been systematically evaluated. However, such efficacy and lack of pharmacokinetic interaction between aripiprazole and lithium or valproate can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and paediatric patients.

      SOURCE: Bristol-Myers Squibb Company



      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send